|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
First published online November 3, 2003
doi: 10.1242/10.1242/jcs.00806
Research Article |
1 Department of Neurology and Neurological Science, Stanford University School of Medicine, Stanford, California, 94305-5235, USA
2 Neurology Service and GRECC, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, 94304, USA
* Author for correspondence (e-mail: rando{at}stanford.edu)
Accepted 28 July 2003
Caveolins are membrane proteins that are the major coat proteins of caveolae, specialized lipid rafts in the plasma membrane that serve as scaffolding sites for many signaling complexes. Among the many signaling molecules associated with caveolins are the Src tyrosine kinases, whose activation regulates numerous cellular functions including the balance between cell survival and cell death. Several mutations in the muscle-specific caveolin, caveolin-3, lead to a form of autosomal dominant muscular dystrophy referred to as limb girdle muscular dystrophy type 1C (LGMD-1C). One of these mutations (here termed the `TFT mutation') results in a deletion of a tripeptide (
TFT(63-65)) that affects the scaffolding and oligomerization domains of caveolin-3. This mutation causes a 90-95% loss of caveolin-3 protein levels and reduced formation of caveolae in skeletal muscle fibers. However, the effects of this mutation on the specific biochemical processes and cellular functions associated with caveolae have not been elucidated. We demonstrate that the TFT caveolin-3 mutation in post-mitotic skeletal myotubes causes severely reduced localization of caveolin-3 to the plasma membrane and to lipid rafts, and significantly inhibits caveolar function. The TFT mutation reduced the binding of Src to caveolin-3, diminished targeting of Src to lipid rafts, and caused abnormal perinuclear accumulation of Src. Along with these alterations of Src localization and targeting, there was elevated Src activation in myotubes expressing the TFT mutation and an increased incidence of apoptosis in those cells compared with control myotubes. The results of this study demonstrate that caveolin-3 mutations associated with LGMD-1C disrupt normal cellular signal transduction pathways associated with caveolae and cause apoptosis in muscle cells, all of which may reflect pathogenetic pathways that lead to muscle degeneration in these disorders.
Key words: Caveolin-3, Caveolae, Limb girdle muscular dystrophy, Lipid rafts, Signal transduction, Src kinase
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati
Twitter What's this?
This article has been cited by other articles:
![]() |
D. Merrick, L. K. J. Stadler, D. Larner, and J. Smith Muscular dystrophy begins early in embryonic development deriving from stem cell loss and disrupted skeletal muscle formation Dis. Model. Mech., July 1, 2009; 2(7-8): 374 - 388. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Cai, N. Weisleder, J.-K. Ko, S. Komazaki, Y. Sunada, M. Nishi, H. Takeshima, and J. Ma Membrane Repair Defects in Muscular Dystrophy Are Linked to Altered Interaction between MG53, Caveolin-3, and Dysferlin J. Biol. Chem., June 5, 2009; 284(23): 15894 - 15902. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Davies, S. Sarkar, and D. C. Rubinsztein Wild-type PABPN1 is anti-apoptotic and reduces toxicity of the oculopharyngeal muscular dystrophy mutation Hum. Mol. Genet., April 15, 2008; 17(8): 1097 - 1108. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Liu, D. J. Burkin, and S. J. Kaufman Increasing {alpha}7{beta}1-integrin promotes muscle cell proliferation, adhesion, and resistance to apoptosis without changing gene expression Am J Physiol Cell Physiol, February 1, 2008; 294(2): C627 - C640. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Riechman, R. D. Andrews, D. A. MacLean, and S. Sheather Statins and Dietary and Serum Cholesterol Are Associated With Increased Lean Mass Following Resistance Training J. Gerontol. A Biol. Sci. Med. Sci., October 1, 2007; 62(10): 1164 - 1171. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Bellott, K. C. Patel, and T. J. Burkholder Reduction of caveolin-3 expression does not inhibit stretch-induced phosphorylation of ERK2 in skeletal muscle myotubes J Appl Physiol, April 1, 2005; 98(4): 1554 - 1561. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. W. Cohen, R. Hnasko, W. Schubert, and M. P. Lisanti Role of Caveolae and Caveolins in Health and Disease Physiol Rev, October 1, 2004; 84(4): 1341 - 1379. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Lapidos, R. Kakkar, and E. M. McNally The Dystrophin Glycoprotein Complex: Signaling Strength and Integrity for the Sarcolemma Circ. Res., April 30, 2004; 94(8): 1023 - 1031. [Abstract] [Full Text] [PDF] |
||||